Loading...
Market
What percentage of Stryker's 2025 revenue will be contributed by Inari Medical products?
3
Resolution / Starting Odds
Less than 5% • 25%
5-10% • 25%
10-15% • 25%
More than 15% • 25%
Stryker's financial reports and earnings releases
Story
Stryker to Acquire Inari Medical for $4.9 Billion at $80/Share, Focusing on VTE Treatments
Jan 6, 2025, 09:09 PM
Stryker Corp. has announced a definitive agreement to acquire Inari Medical, Inc. for $80 per share in cash, valuing the deal at approximately $4.9 billion. This acquisition will allow Stryker to expand its offerings into the high-growth peripheral vascular segment, focusing on venous thromboembolism (VTE) treatments. Inari's innovative product portfolio, which includes mechanical thrombectomy solutions for peripheral vascular diseases such as deep vein thrombosis and pulmonary embolism, complements Stryker's existing Neurovascular business. The transaction is expected to close by the end of the first quarter of 2025, pending customary closing conditions including regulatory approvals.
View original story
Similar markets
Delayed • 25%
Cancelled • 25%
Modified Terms • 25%
Completed • 25%
Discontinued Products • 25%
Full Integration • 25%
Independent Operation • 25%
Partial Integration • 25%
Negative • 25%
Neutral • 25%
Positive • 25%
Unchanged • 25%
Yes • 50%
No • 50%
No • 50%
Yes • 50%
Less than 10% • 25%
10-20% • 25%
More than 30% • 25%
20-30% • 25%
20% to 40% • 25%
Less than 20% • 25%
More than 60% • 25%
40% to 60% • 25%
5% to 10% • 25%
Less than 5% • 25%
10% to 15% • 25%
More than 15% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
More than 60% • 25%
41% to 60% • 25%
20% to 40% • 25%
Less than 20% • 25%